Respiratory Syncytial Virus Infections
"Respiratory Syncytial Virus Infections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.
| Descriptor ID |
D018357
|
| MeSH Number(s) |
C02.782.580.600.620.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus Infections".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus Infections".
This graph shows the total number of publications written about "Respiratory Syncytial Virus Infections" by people in this website by year, and whether "Respiratory Syncytial Virus Infections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 0 | 4 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 0 | 5 |
| 2020 | 6 | 0 | 6 |
| 2021 | 8 | 0 | 8 |
| 2022 | 5 | 0 | 5 |
| 2023 | 19 | 0 | 19 |
| 2024 | 13 | 2 | 15 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus Infections" by people in Profiles.
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
-
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. Obstet Gynecol. 2025 Feb 01; 145(2):147-156.
-
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
-
Home-Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021-2022-A Pilot Study. Influenza Other Respir Viruses. 2024 12; 18(12):e70034.
-
Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the Pneumonia Etiology Research for Child Health (PERCH) study experience. Clin Microbiol Infect. 2025 Mar; 31(3):441-450.
-
Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012 - 2018. BMC Infect Dis. 2024 Oct 09; 24(1):1128.
-
The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children S Afr Med J. 2024 10 08; 114(10):e2582.
-
Impact of Respiratory Syncytial Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection on Clinical Severity and Outcomes Among Children Hospitalized With Lower Respiratory Tract Infections in Soweto, South Africa. Pediatr Infect Dis J. 2025 Feb 01; 44(2):107-111.
-
Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children. Pediatrics. 2024 Oct 01; 154(4).
-
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect Dis. 2024 Dec; 24(12):e747-e761.